https://markets.businessinsider.com/news/stocks/scynexis-reports-second-quarter-2025-financial-results-and-provides-corporate-update-1035032961
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Markets...
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An ad...
second quarterfinancial results
https://markets.businessinsider.com/news/stocks/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-1035979917
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct...
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst gr...
https://markets.businessinsider.com/news/stocks/scynexis-announces-federal-funding-of-collaboration-between-hackensack-meridian-cdi-and-johns-hopkins-researchers-to-develop-new-therapeutics-including-novel-fungerps-for-resistant-fungal-infections-1035569837
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns...
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistan...
federal funding
https://adisinsight.springer.com/patents/800031918
Ibrexafungerp - SCYNEXIS - AdisInsight
adisinsight
https://markets.businessinsider.com/news/stocks/scynexis-resumes-patient-dosing-in-phase-3-mario-study-1034770270
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | Markets Insider
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M mi...
in phaseresumespatientdosing